Showing 211-220 of 3714 results for "".
- Pfizer’s JAK Inhibitor Improves Moderate-to-Severe AD Symptomshttps://practicaldermatology.com/news/pfizers-jak-inhibitor-improves-mild-to-moderate-ad-symptoms/2460413/Results from the second pivotal trial for abrocitinib reinforce the potential symptom relief that this Janus kinase 1 (JAK1) inhibitor offers patients living with moderate to severe atopic dermatitis (AD). Abrocitinib is an investigational oral once-daily JAK1 inhibitor being studied in patients a…
- Tremfya Shows Improvement in PsA Joint and Skin Symptomshttps://practicaldermatology.com/news/tremfya-shows-improvement-in-psa-joint-and-skin-symptoms/2460412/Tremfya (guselkumab) demonstrated improvements in multiple clinical outcomes including joint symptoms, skin symptoms, soft tissue inflammation, physical function and reduction in radiographic progression at week 52 in adult patients with active psoriatic arthritis (PsA), according to data from two …
- Asana BioSciences’ JAK/SYK Inhibitor Performs Well in Phase 2b Study of Hand Eczemahttps://practicaldermatology.com/news/asana-biosciences-jaksyk-inhibitor-performs-well-in-phase-2b-study-of-hand-eczema/2460409/Asana BioSciences’ investigational oral Janus kinase family (JAK) and spleen tyrosine kinase (SYK) inhibitor gusacitinib (ASN002) showed rapid and significant improvement in a phase 2b study of 97 adult patients with moderate-to-severe chronic hand eczema. The study was a randomized, double-blind,…
- FDA Approves Ortho Dermatologics' Jublia to Treat Onychomycosis in Patients As Young As Six Years Oldhttps://practicaldermatology.com/news/fda-approves-ortho-dermatologics-jublia-to-treat-onychomycosis-in-patients-as-young-as-six-years-old/2460371/Bausch Health Companies Inc. and its dermatology business, Ortho Dermatologics received FDA approval for a supplemental New Drug Application (sNDA) for Jublia (efinaconazole) topical solution, 10%, a treatment for onychomycosis, a fungal infection of the toenails, which extends the age range includ…
- Can JAK Inhibition Put the Brakes on COVID-19-Associated Cytokine Storm? Incyte Hopes Sohttps://practicaldermatology.com/news/can-jak-inhibition-put-the-brakes-on-covid-19-associated-cytokine-storm-incyte-hopes-so/2460355/Incyte’s JAK inhibitor may play a role in stopping COVID-19-associated cytokine storms. Incyte is starting RUXCOVID, a global, randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating the efficacy and safety of ruxolitinib (Jakafi) plus standard-of-care (SoC) in patients aged…
- Isdin Taps Professional Golfer Jessica Korda As New Sports Ambassadorhttps://practicaldermatology.com/news/isdin-taps-professional-golfer-jessica-korda-as-new-sports-ambassador-1/2460330/Professional golfer and LPGA star Jessica Korda is ISDIN’s new sports ambassador. As part of the campaign, Korda is sharing how she keeps her skin looking its best on and off the golf course with ISDIN products. "ISDIN formulates unique and innovative products with advanced ingredients that are r…
- Evolve BioSystems and Janssen to Study the Impact of B. infantis EVC001 for AD Prevention in Infantshttps://practicaldermatology.com/news/evolve-biosystems-and-janssen-to-study-the-impact-of-b-infantis-evc001-for-ad-prevention-in-infants/2460324/Evolve BioSystems, Inc. and Janssen Research & Development, LLC, are partnering to conduct a study looking at the potential role of B. infantis EVC001 in preventing early childhood atopic dermatitis (AD). The study will assess the effects of introducing a specific gut bacterium, Bifidobacterium lo…
- 30% of Americans’ Jobs Negatively Impacted by COVID-19, Economic Fallouthttps://practicaldermatology.com/news/30-of-americans-jobs-negatively-impacted-by-covid-19-economic-fallout/2460317/While 35 percent of 1,000 Americans surveyed by LendEDU say that that their jobs have not been impacted by the Coronavirus, six percent report losing their job, 13 percent report that hours have been partially cut, and 11 percent have had hours cut entirely, though they still have their jobs. Of t…
- Allergan Rolls Out New DTC Juvéderm Lips Campaignhttps://practicaldermatology.com/news/allergan-rolls-out-new-dtc-juvederm-lips-campaign/2460281/Allergan is launching its new direct-to-consumer campaign for Juvéderm lips with ads and creative deploying across TV, social media, and digital advertising. As part of the new campaign, New York City-based facial plastic surgeon Dara Liotta, MD, reality television personality Audrina Patridge, an…
- Proscia and Johns Hopkins School of Medicine Collaborate to Bring AI Applications to High-Impact Diseases and Specialties in Pathologyhttps://practicaldermatology.com/news/proscia-and-johns-hopkins-school-of-medicine-collaborate-to-bring-ai-applications-to-high-impact-diseases-and-specialties-in-pathology/2460231/Proscia, a provider of AI-enabled digital pathology software, and Johns Hopkins School of Medicine, one of the leading academic medical centers in the US, will collaborate on the development of computational applications that incorporate artificial intelligence (AI) to advance the practice of patho…